Dr Jeffrey Goh explains ITTACc – ANZGOG’s latest cervical cancer study

ITTACc is ANZGOG’s phase II, randomised multi-centre non-comparative trial of sitravatinib in recurrent or metastatic cervical cancer that have progressed after standard therapies. ANZGOG spoke with ITTACc Principal Investigator, Dr Jeffrey Goh, who explained the study [...]